{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Ulrike Leurs"}, {"accession": "MS:1000589", "name": "contact email", "value": "ulrike.leurs@gmail.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "University of Copenhagen, Denmark"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Jesper V. Olsen"}, {"accession": "MS:1000589", "name": "contact email", "value": "jesper.olsen@cpr.ku.dk"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Novo Nordisk Foundation Center for Protein Research, University of Copenhagen (Denmark)"}]}], "datasetFiles": [{"accession": "MS:1002851", "name": "Other type file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/checksum.txt"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL170.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL171.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL172.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL173.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL174.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL175.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL176.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL177.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL178.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL179.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL180.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL194.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL196.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/20170401_QE3_nLC05_ChKe_COLLAB_UL197.raw"}, {"accession": "MS:1002845", "name": "Associated file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/MS Sample Info.xlsx"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679/proteinGroups.xlsx"}], "description": "Ca2+/calmodulin-dependent protein kinase II alpha (CaMK2A) is an emerging drug target incerebral ischemia for which limited therapeutic options exist. Here we show that small-molecule analogs of the brain metabolite gamma-hydroxybutyric acid (GHB) afford neuroprotection via interaction specifically with the CaMK2A hub domain. Identification of CaMK2A as the GHB analog target was achieved by homogenate photoaffinity labeling followed by quantitative proteomics", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD019679"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD019679"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD019679"}], "instruments": [{"accession": "MS:1002523", "name": "Q Exactive HF"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "QExactive HF, brain homogenate, affinity purification, photoaffinity labeling, rat"}], "modifications": [{"accession": "MOD:01885", "name": "biotinylated residue"}], "publications": [{"terms": [{"accession": "MS:1002858", "name": "Dataset with its publication pending"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Rattus norvegicus (Rat)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "10116"}]}], "title": "GHB analogs confer neuroprotection through specific interaction with the CaMKII  hub domain"}